Compare BNTC & MYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | MYN |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.7M | 380.8M |
| IPO Year | N/A | N/A |
| Metric | BNTC | MYN |
|---|---|---|
| Price | $11.61 | $10.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $27.67 | N/A |
| AVG Volume (30 Days) | ★ 116.3K | 86.0K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.12% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.70 | $8.47 |
| 52 Week High | $17.15 | $10.62 |
| Indicator | BNTC | MYN |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 48.63 |
| Support Level | $11.45 | $9.91 |
| Resistance Level | $12.88 | $10.15 |
| Average True Range (ATR) | 0.63 | 0.11 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 31.75 | 32.94 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.